Extract
We read with great interest the article by Pontali et al. [1], entitled “Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence”. In response to this paper and the debate on potential QTc prolongation in clofazimine- and bedaquiline-containing multidrug-resistant tuberculosis (MDR-TB) treatment regimens [2, 3], we assessed QTc prolongation during clofazimine use in treatment of disease caused by nontuberculous mycobacteria (NTM). This is important as NTM disease treatment typically includes multiple potential QTc-prolonging antibiotics, including macrolides, fluoroquinolones and, increasingly, clofazimine [4].
Abstract
Clofazimine does not lead to significant QT interval prolongation in the treatment of nontuberculous mycobacteria http://ow.ly/sXC330lIbI8
Footnotes
Conflict of interest: S.M.H. Zweijpfenning reports grants and non-financial support for a clinical trial from Novartis and Insmed, outside the submitted work.
Conflict of interest: H. van Groningen has nothing to disclose.
Conflict of interest: J. van Ingen has nothing to disclose.
Conflict of interest: C. Magis-Escurra has nothing to disclose.
Conflict of interest: M.J. Boeree has nothing to disclose.
Conflict of interest: D. Wagner has nothing to disclose.
Conflict of interest: H. Bax nothing to disclose.
Conflict of interest: C. Andrejak has nothing to disclose.
Conflict of interest: R. Wener has nothing to disclose.
Conflict of interest: A. Rahman has nothing to disclose.
Conflict of interest: H. Kunst has nothing to disclose.
Conflict of interest: N. Lorent has nothing to disclose.
Conflict of interest: M.A. Brouwer has nothing to disclose.
Conflict of interest: W. Hoefsloot reports grants from Insmed Corp, during the conduct of the study.
- Received April 4, 2018.
- Accepted August 22, 2018.
- Copyright ©ERS 2018
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
